000307530 001__ 307530
000307530 005__ 20260220120942.0
000307530 0247_ $$2doi$$a10.1007/s00259-025-07686-1
000307530 0247_ $$2pmid$$apmid:41483304
000307530 0247_ $$2ISSN$$a1619-7070
000307530 0247_ $$2ISSN$$a1619-7089
000307530 037__ $$aDKFZ-2026-00035
000307530 041__ $$aEnglish
000307530 082__ $$a610
000307530 1001_ $$00009-0006-5346-6965$$aDebus, Josefin$$b0
000307530 245__ $$a68Ga-FAPI PET/CT for non-invasive characterization and activity assessment of ulcerative colitis and Crohn´s disease.
000307530 260__ $$aHeidelberg [u.a.]$$bSpringer-Verl.$$c2026
000307530 3367_ $$2DRIVER$$aarticle
000307530 3367_ $$2DataCite$$aOutput Types/Journal article
000307530 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1767622283_2785347
000307530 3367_ $$2BibTeX$$aARTICLE
000307530 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000307530 3367_ $$00$$2EndNote$$aJournal Article
000307530 500__ $$aepub
000307530 520__ $$aInflammatory Bowel Diseases (IBD) comprise ulcerative colitis (UC) and Crohn's disease (CD). Management of IBD requires assessment of disease activity, severity, extent and complications. Here, we describe the signal behavior of both CD and UC in 68Gallium- fibroblast activation protein inhibitor-based radiopharmaceuticals-46-positron emission tomography (68Ga-FAPI-46-PET) and evaluate the potential of 68Ga-FAPI-46-PET for activity assessment in IBD.This analysis includes data of 43 IBD patients and 43 control patients examined by 68Ga-FAPI-46-PET/computed tomography (CT). Disease activity of IBD patients was assessed by colonoscopy. FAPI-positive gastrointestinal tract (GIT)-findings and healthy appearing GI structures were contoured. Non-IBD related FAPI-positive GIT-findings were ruled out by interdisciplinary consensus. Static and dynamic PET-parameters of FAPI-positive IBD lesions and healthy appearing GI structures were extracted and PET signalling was analyzed with respect to IBD subtype and disease activity.We examined 20 CD patients and 23 UC patients (29 with active, 14 with inactive disease). FAPI-uptake in most healthy appearing GI structures of IBD patients was significantly increased compared to controls. Of 80 FAPI-positive GIT-findings, 14 were ruled out as non-IBD related and 66 FAPI-positive IBD lesions were analyzed. We observed equally high lesional FAPI-uptake in CD and UC. All patients with active disease showed at least one intensively FAPI-positive IBD lesion, while only 4/14 patients with inactive disease showed any FAPI-positive IBD lesion. Lesional and patientwise FAPI-uptake was significantly higher in active than in inactive disease. FAPI-positive IBD lesions showed a characteristic kinetic behaviour with two types of uptake patterns - one showing a continuous increase and the other an early peak followed by a plateau.68Ga-FAPI-46-PET/CT appears promising for assessing disease activity in terms of fibroblast activation in both CD and UC.
000307530 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000307530 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000307530 650_7 $$2Other$$aCrohn´s disease
000307530 650_7 $$2Other$$aFAPI
000307530 650_7 $$2Other$$aFibroblasts
000307530 650_7 $$2Other$$aIBD disease activity
000307530 650_7 $$2Other$$aUlcerative colitis
000307530 7001_ $$avon Götze, Isabelle$$b1
000307530 7001_ $$aBrandt, Johannes$$b2
000307530 7001_ $$aEhehalt, Robert$$b3
000307530 7001_ $$aSpektor, Anna-Maria$$b4
000307530 7001_ $$aMildenberger, Philipp$$b5
000307530 7001_ $$aGauss, Annika$$b6
000307530 7001_ $$aLang, Matthias$$b7
000307530 7001_ $$aGlatting, Frederik M$$b8
000307530 7001_ $$aSchreckenberger, Mathias$$b9
000307530 7001_ $$aKalla, Rahul$$b10
000307530 7001_ $$0P:(DE-He78)13a0afba029f5f64dc18b25ef7499558$$aHaberkorn, Uwe$$b11$$udkfz
000307530 7001_ $$00000-0001-7609-243X$$aRöhrich, Manuel$$b12
000307530 773__ $$0PERI:(DE-600)2098375-X$$a10.1007/s00259-025-07686-1$$pnn$$tEuropean journal of nuclear medicine and molecular imaging$$vnn$$x1619-7070$$y2026
000307530 8564_ $$uhttps://inrepo02.dkfz.de/record/307530/files/s00259-025-07686-1.pdf$$yOpenAccess
000307530 8564_ $$uhttps://inrepo02.dkfz.de/record/307530/files/s00259-025-07686-1.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000307530 909CO $$ooai:inrepo02.dkfz.de:307530$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000307530 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)13a0afba029f5f64dc18b25ef7499558$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000307530 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000307530 9141_ $$y2026
000307530 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-05
000307530 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-05
000307530 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-05
000307530 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-05
000307530 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J NUCL MED MOL I : 2022$$d2024-12-05
000307530 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-05
000307530 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2024-12-05$$wger
000307530 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-05
000307530 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000307530 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-05
000307530 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR J NUCL MED MOL I : 2022$$d2024-12-05
000307530 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-05
000307530 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-05
000307530 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-05
000307530 9201_ $$0I:(DE-He78)E060-20160331$$kE060$$lE060 KKE Nuklearmedizin$$x0
000307530 980__ $$ajournal
000307530 980__ $$aVDB
000307530 980__ $$aUNRESTRICTED
000307530 980__ $$aI:(DE-He78)E060-20160331
000307530 9801_ $$aFullTexts